Want to join the conversation?
Weston, MA-based biotech firm $BIIB posted 1Q16 sales of $2.7Bil, up 7% YoverY, driven by increased revenues from TECFIDERA, ELOCTATE and ALPROLIX. For the quarter, net income attributable to $BIIB was $971MM, or $4.43 per diluted share, up 18% from $823MM, or $3.49 per diluted share, in the prior year quarter.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.